Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
With strong data in hand Astrazeneca now needs to get cardiologists on board, and stay ahead of Lilly and Boehringer.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Citing study failure, Sanofi terminates its tie-up with Lexicon covering Zynquista; not so fast, says Lexicon, and claims breach of contract.
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.